Hims & Hers Health stock beat on earnings but suffered a steep sales slowdown in Q4. Hims & Hers is trying to figure out how to grow without selling GLP-1 drugs. Hims & Hers reported its earnings for ...

Hims & Hers Health is not out of the woods yet, sitting near yesterday's 17-month lows At last glance, shares of Hims & Hers Health Inc (NYSE:HIMS) are up 0.5% to trade at $15.91, after the wellness ...

Hims & Hers is facing battles on multiple fronts as it seeks to maintain its lucrative business in copycat weight loss drugs. Federal regulators are seeking to rein in the online telemedicine platform ...

Hims & Hers stock dropped 77% from its high due to GLP-1 regulatory and legal pressure. Eucalyptus brings $450M in annualized revenue growing at triple-digit rates to Hims & Hers. Are you ahead, or ...

Hims & Hers Health stock fell Tuesday, the day after the telehealth company posted mixed quarterly results and issued a weak outlook for the current quarter.

Hims & Hers Health said on Thursday it will acquire Australian digital ⁠health company Eucalyptus in a deal valued at up to $1.15 billion, as the U.S. telehealth platform seeks to broaden its ...

Hims & Hers executives struck a confident tone about the company's growth prospects Monday as it launches new specialties and rapidly expands into international markets. But investors are concerned ...

Traditionally, if you wanted prescription medication for weight loss, hair regrowth, or erectile dysfunction, you had to make an appointment with your doctor. Needless to say, that isn’t always a ...

Hims & Hers Health said Saturday that it would no longer offer a compounded pill version of the popular weight-loss medicine Wegovy, following increased scrutiny from federal regulators.

Hims & Hers Health HIMS-3.47%decrease; red down pointing triangle has agreed to acquire digital health company Eucalyptus in a deal valued at $1.15 billion as it seeks to expand its geographic reach.